APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

NCT01750788 ·Status: COMPLETED

Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors

NCT06383741 ·Status: RECRUITING

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

NCT03887780 ·Status: COMPLETED

Rivaroxaban Acute Stroke Safety Study

NCT02279940 ·Status: COMPLETED

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation

NCT03284762 ·Status: COMPLETED

RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke

NCT02129920 ·Status: UNKNOWN

Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke

NCT02159287 ·Status: UNKNOWN ·Phase: PHASE2

Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

NCT04218266 ·Status: COMPLETED ·Phase: PHASE2

BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis

NCT07237308 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation

NCT02147444 ·Status: UNKNOWN

Real-Life Evidence on Stroke Prevention in SPAF

NCT02485873 ·Status: COMPLETED

Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial

NCT02818868 ·Status: COMPLETED

TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation

NCT02961348 ·Status: COMPLETED ·Phase: NA

Intravenous Thrombolysis and NOAC

NCT06749834 ·Status: RECRUITING ·Phase: PHASE3

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

NCT02387229 ·Status: TERMINATED ·Phase: PHASE3

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

NCT05262322 ·Status: COMPLETED

New Oral Anticoagulants (NOAC) in Stroke Patients

NCT03826927 ·Status: COMPLETED

Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

NCT00126139 ·Status: TERMINATED ·Phase: PHASE3

PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

NCT03996772 ·Status: COMPLETED ·Phase: PHASE3

Rivaroxaban Evaluation in Real Life Settings

NCT02444221 ·Status: COMPLETED

Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis

NCT06058130 ·Status: RECRUITING ·Phase: NA

The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation

NCT06864052 ·Status: NOT_YET_RECRUITING ·Phase: NA

Addressing Real-world Anticoagulant Management Issues in Stroke

NCT02478177 ·Status: COMPLETED

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

NCT03766581 ·Status: COMPLETED ·Phase: PHASE2

Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

NCT03749057 ·Status: COMPLETED ·Phase: PHASE4